In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.
There has been an evolution in metrics measuring changes in physical function and well-being in patients with myasthenia gravis, Srikanth Muppidi, MD, said.